Largest CIDP Trial Offers Promising Results for Drug Combo
Nearly 70% of patients showed improvement after treatment with efgartigimod plus rHuPH20 in phase 2 of the largest randomized controlled trial for CIDP to date.
Stay updated with breaking news from Adverse Effects. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nearly 70% of patients showed improvement after treatment with efgartigimod plus rHuPH20 in phase 2 of the largest randomized controlled trial for CIDP to date.
The US Centers for Disease Control and Prevention issued an advisory Tuesday about the risks of counterfeit or mishandled Botox injections after dangerous fake versions of the product have been found in several states.
The authors "identified a need for expert-based guidelines for prescribing and monitoring LDOM use in hair loss patients."
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.
Last year saw more than 50 new drug approvals, many of which may help internists better manage several common conditions in their patients.